INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC

Core Insights - Holzer & Holzer, LLC is investigating whether Travere Therapeutics, Inc. complied with federal securities laws following the FDA's extension of the review timeline for its supplemental New Drug Application for FILSPARI® in focal segmental glomerulosclerosis, which led to a drop in the company's stock price [1] Company Summary - Travere Therapeutics, Inc. disclosed on January 13, 2026, that the FDA has extended the review timeline for its supplemental New Drug Application for FILSPARI® [1] - The announcement resulted in a decline in the company's stock price [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in litigation, including shareholder class action and derivative litigation [3] - The firm has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]